Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

Phase 2

Completed

• Conditions: Diabetic Macular Edema
• Interventions: Drug: Luminate 1.0mg; Drug: Luminate 2.0mg; Drug: Luminate 3.0mg; Drug: Avastin; Drug: Luminate 0.5mg

• Registration Number: NCT02348918
• Lead Sponsor: Allegro Ophthalmics, LLC

Brief Summary

A Phase 2 Multi center, Randomized, Controlled, Double-Masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate® (Alg-1001) As Compared To Avastin® In The Treatment Of Diabetic Macular Edema

Detailed Description

To evaluate the safety and efficacy of Luminate® (ALG-1001) as compared to Avastin® in patients with diabetic macular edema

- Stage 1: 120 eligible subjects with DME will be enrolled and randomized to one of 4 treatment groups at an allocation ratio of 1:1:1:1, i.e., one of three doses (1.0 mg, 2.0 mg and 3.0 mg) of Luminate intravitreal injection or Avastin intravitreal injection. Subjects will be followed monthly for 24 weeks (6 months).

Stage 2 (select sites): 75 eligible subjects with DME will be enrolled and randomized to one of 5 treatment groups at an allocation ratio of 1:1:1:1:1; i.e., one of 2 doses of Luminate intravitreal injection or Avastin intravitreal injection (0.5 mg and 1.0 mg). Subjects will be followed monthly for 20 weeks (5 months).

Study Timeline

• Study Start: 2014-10-13
• Study First Submitted: 2015-01-12
• Study First Submitted QC: 2015-01-23
• Study First Posted: 2015-01-28
• Primary Completion: 2017-05-16
• Study Completion: 2017-06-13
• Results First Submitted: 2018-08-31
• Status Verified: 2018-12
• Results First Submitted QC: 2018-12-05
• Last Update Submitted: 2018-12-05
• Results First Posted: 2018-12-07
• Last Update Posted: 2018-12-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 218

Inclusion Criteria

• Male or female, 18 years of age or older.

• Study eye with clinically significant diabetic macular edema (DME) with central subfield thickness ≥ 350µm on spectral domain OCT

• Best corrected visual acuity (BCVA) of 20/50 to 20/320 ETDRS equivalent (65 letters to 23 letters) in the study eye, with BCVA decrement primarily attributable to DME.

• Treatment naïve, i.e., no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment.

• In the investigator's opinion, the subject still has significant intraretinal fluid with room for improvement in both macular edema and BCVA.

• Intra-Ocular Pressure (IOP) is under control (i.e., IOP

  ≤ 25 mm in the study eye) and study eye is not receiving any IOP lowering drops.

• Willing and able to return for all study visits.

• Able to meet the extensive post-op evaluation regimen.

• Understands and signs the informed consent form.

Exclusion Criteria

• Active proliferative diabetic retinopathy (PDR) in the study eye such as NVE, NVD, vitreous hemorrhage, or neovascular glaucoma.
• Uncontrolled hypertension defined as systolic >180 mmHg or > 160 mmHg on 2 consecutive measurements or diastolic > 100 mmHg on optimal medical regimen
• Screening HgA1c blood test > 10.0
• Focal laser photocoagulation or intravitreal/periocular steroids of any type in the study eye within the last 90 days prior to study enrollment.
• A history of intravitreal anti-VEGF injection of any type in the study eye within the last 45 days prior to study enrollment.
• History of rhegmatogenous retinal detachment, retinal tear(s), or traction retinal detachments in the study eye.
• Epiretinal membrane and/or vitreomacular traction in the study eye as determined by the central reading center.
• Previous pars plana vitrectomy in the study eye
• Any intraocular surgery in the study eye within the last 90 days prior to study enrollment.
• YAG laser treatment in the study eye in last 30 days prior to study enrollment.
• High myopia in the study eye, with a spherical equivalent of >8.00D at screening
• Other ocular pathologies that in the investigator's opinion would interfere with the subject's vision in the study eye.
• Chronic or recurrent uveitis.
• Ongoing ocular infection or inflammation in either eye.
• A history of cataract surgery complications/vitreous loss in the study eye.
• Congenital eye malformations in the study eye.
• A history of penetrating ocular trauma in the study eye.
• Mentally handicapped.
• Pregnant female, as determined for women less than 60 years old by a positive urine pregnancy test during the screening window.
• Nursing female.
• Currently participating in any other clinical research study.
• Contraindication to the study medication.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Luminate 1.0mg group	Luminate 1.0mg	Stage 1- Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
Luminate 2.0mg group	Luminate 2.0mg	Stage 1 -Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
Luminate 3.0mg group	Luminate 3.0mg	Stage 1- Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
Avastin® group	Avastin	Stage 1- Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required.
Avastin then Luminate 1.0 mg IVT + sham injection	Luminate 1.0mg	Stage 2 - Week 0 (Baseline): Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 1.0 mg IVT + sham injection Weeks 12 and 16: Sham IVT
Avastin then Luminate 1.0 mg IVT + sham injection	Avastin	Stage 2 - Week 0 (Baseline): Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 1.0 mg IVT + sham injection Weeks 12 and 16: Sham IVT
Avastin then Luminate 0.5 mg IVT + sham injection	Avastin	Stage 2- Week 0 (Baseline); Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + sham injection Weeks 12 and 16: Sham IVT
Avastin then Luminate 0.5 mg IVT + sham injection	Luminate 0.5mg	Stage 2- Week 0 (Baseline); Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + sham injection Weeks 12 and 16: Sham IVT
Sham then Luminate 0.5 mg IVT + Avastin 1.25 mg IVT	Avastin	Stage 2 : Week 0: Sham IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
Sham then Luminate 0.5 mg IVT + Avastin 1.25 mg IVT	Luminate 0.5mg	Stage 2 : Week 0: Sham IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
Avastin 1.25 mg + Sham IVT	Luminate 0.5mg	Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Avastin 1.25 mg + Sham IVT Weeks 12 and 16: Avastin PRN
Sham then Luminate 1.0 mg + Avastin 1.25 mg IVT	Luminate 1.0mg	Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Luminate 1.0 mg + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
Sham then Luminate 1.0 mg + Avastin 1.25 mg IVT	Avastin	Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Luminate 1.0 mg + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT

Primary Outcome Measures

Name	Time	Method
Change in BCVA at Week 24	Value of 24 Weeks minus baseline value	Primary efficacy outcome is BCVA changes at Week 24 as compared to baseline

Trial Locations

Locations (17)

Retina Specialty Institute; 🇺🇸 Pensacola, Florida, United States

Orange County Retina Medical Group; 🇺🇸 Santa Ana, California, United States

Center for Retina and Macular Disease; 🇺🇸 Winter Haven, Florida, United States

Island Retina; 🇺🇸 Shirley, New York, United States

Austin Retina Associates; 🇺🇸 Austin, Texas, United States

Spokane Eye Clinical Research; 🇺🇸 Spokane, Washington, United States

Charlotte EENT Associates; 🇺🇸 Charlotte, North Carolina, United States

Black Hills Regional Eye Institute; 🇺🇸 Rapid City, South Dakota, United States

Retina Consultant of Houston; 🇺🇸 Houston, Texas, United States

Associated Retina Consultants; 🇺🇸 Phoenix, Arizona, United States

Retina Vitreous Associates Medical Group; 🇺🇸 Beverly Hills, California, United States

Northern California Retina Vitreous Associates; 🇺🇸 Mountain View, California, United States

West Coast Retina; 🇺🇸 San Francisco, California, United States

Wilmer Eye Institute at John Hopkins University; 🇺🇸 Baltimore, Maryland, United States

TLC Eye Group; 🇺🇸 Jackson, Michigan, United States

New England Retina Associates; 🇺🇸 New London, Connecticut, United States

Florida Eye Clinic; 🇺🇸 Altamonte Springs, Florida, United States